| アブストラクト | BACKGROUND: Polymyxins have been regarded as last-line treatment for multidrug-resistant gram-negative bacterial infections. Nonetheless, concerns regarding toxicity persist. This study aimed to explore and compare potential adverse events (AEs) between colistin and polymyxin B (PMB). METHODS: Outpatient antibiotic use associated with acute upper respiratory infections in China: a nationwide cross-sectional study Polymyxins-related AEs were retrieved from the U.S. Food and Drug Administration Adverse Event Reporting System between 2004 and 2022. Potential signals were estimated by the reporting odds ratio (ROR), and subgroup analyses were preformed to adjust for potential factors in AEs with significant disproportionality. RESULTS: Analysis of 3,915 records involving 718 patients revealed a higher disproportionality of renal and urinary disorders (ROR 1.62, 95% CI 1.01-2.59) and acute kidney injury (ROR 1.75, 95% CI 1.07-2.87) with colistin treatment. Conversely, colistin exhibited a lower risk for neurotoxicity (ROR 0.47, 95% CI 0.30-0.73). Seven cases of skin hyperpigmentation were reported with PMB, whereas none were reported with colistin. Over 80% of cases involving polymyxin-related AEs occurred during the first two weeks of therapies, with a median onset time of 4.5 days. CONCLUSIONS: Outpatient antibiotic use associated with acute upper respiratory infections in China: a nationwide cross-sectional study Patients received colistin displayed a higher potential risk of nephrotoxicity but a lower risk of neurotoxicity. Clinicians should be vigilant in monitoring the AEs of hyperpigmentation disorders induced by PMB. |
|---|
| ジャーナル名 | Expert opinion on drug safety |
|---|
| 投稿日 | 2024/4/28 |
|---|
| 投稿者 | Wu, Tingxi; Shi, Yanfeng; Xu, Chang; Zhu, Bin; Li, Dandan; Li, Zhe; Zhao, Zhigang; Zhang, Yang |
|---|
| 組織名 | Department of Pharmacy, Beijing Tiantan Hospital, Capital Medical University,;Beijing, China.;Center of excellence for Omics Research, National Clinical Research Center for;Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University,;Clinical Trials Institutions for Drugs and Medical devices, Beijing Shijitan;Hospital, Capital Medical University, Beijing, China.;Department of Pharmacy, Beijing Friendship Hospital, Capital Medical University,;Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery Systems,;State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical;Sciences, Peking University, Beijing, China. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/38676603/ |
|---|
